Lawmakers Blast Mylan’s Move to Curb EpiPen Costs as PR Fix

Updated on
  • Drugmaker responding to torrent of political criticism
  • Stock pares early gains Thursday, lost 11% in last three days

Mylan Cuts EpiPen Patient Cost by 50 Percent

Mylan NV’s move to alleviate patients’ cost burden for its $600 EpiPen emergency allergy shots was blasted by members of Congress who called it a public-relations maneuver.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.